Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial
Journal
Breast cancer research and treatment
Journal Volume
192
Journal Issue
3
Date Issued
2022-04
Author(s)
Hickish, Tamas
Mehta, Ajay
Liu, Mei-Ching
Arora, Rajendra Singh
Chang, Yuan-Ching
Yang, Youngsen
Vladimirov, Vladimir
Jain, Minish
Tsang, Janice
Pemberton, Karine
Sadrolhefazi, Behbood
Jin, Xidong
Tseng, Ling-Ming
Abstract
Resistance to HER2 (ErbB2)-targeted therapy may be mediated by other members of the ErbB family. We investigated the efficacy and safety of the irreversible ErbB family blocker, afatinib, alone as first-line therapy in the advanced setting and in combination with vinorelbine or paclitaxel for those who progressed on afatinib monotherapy, in female patients with metastatic breast cancer who had failed or progressed on prior HER2-targeted therapy in the early disease setting.
Subjects
Afatinib; ErbB; HER2; Metastatic breast cancer; Resistance
SDGs
Publisher
SPRINGER
Type
journal article